Ifosfamide, an analogue of the alkylating agent cyclophosphamide, is one of the most active agents in the treatment of small cell lung cancer (SCLC). As a single agent, the drug produces a greater than 50% objective response rate. Recent studies using ifosfamide in combination with other active agents, ie, cisplatin, carboplatin, and etoposide, in the treatment of limited-stage and extensive-stage SCLC have achieved high overall response rates and complete responses (CRs). However, the CR rate is higher in limited-disease patients. Additional studies are needed with the various ifosfamide-containing regimens to precisely define their role in the treatment of SCLC in both limited-disease and extensive disease patients.
|Original language||English (US)|
|Number of pages||9|
|Journal||Seminars in oncology|
|Issue number||1 SUPPL. 1|
|State||Published - Feb 1992|
ASJC Scopus subject areas